[go: up one dir, main page]

GT200000011A - Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevos materiales. - Google Patents

Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevos materiales.

Info

Publication number
GT200000011A
GT200000011A GT200000011A GT200000011A GT200000011A GT 200000011 A GT200000011 A GT 200000011A GT 200000011 A GT200000011 A GT 200000011A GT 200000011 A GT200000011 A GT 200000011A GT 200000011 A GT200000011 A GT 200000011A
Authority
GT
Guatemala
Prior art keywords
acids
salts
derivatives
isoxazolcarboxilic
derivative
Prior art date
Application number
GT200000011A
Other languages
English (en)
Inventor
Jurgen Stoltefuss
Gabriele Braunlich
Berthold Hinzen
Thomas Studemann
Thomas Kramer
Michael Sperzel
Ulrich Nielsch
Martin Bechem
Josef Pernerstorfer
Emanuel Lohrmann
Christoph Gerdes
Klemens Lustig
Lorenz Mayr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000011A publication Critical patent/GT200000011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE ESTOS COMPUESTOS Y DERIVADOS PARA LA OBTENCION DE MEDICAMENTOS PARA LA PROFILAXIS Y/O TRATAMIENTO DE ANEMIAS, NUEVOS ACIDOS ISOXAZOLCARBOXILICOS Y DERIVADOS DE FORMULA GENERAL (I), [EN LA QUE "A,D, E, Y G " REPRESENTAN HIDROGENO, HALOGENO, TRIFLUOROMETILO, HIDROXILO O ALQUILOALCOXI (C1C6) Y "R# " DIFERENTES POSIBILIDADES DE GRUPOS FUNCIONALES QUE PUEDEN FORMAR PARTE DE LA MOLECULA, EL LISTADO DE SUS NOMBRES ESPECIFICOS SE HALLA EN EL DOCUMENTO ORIGINAL], ASI COMO A PROCEDIMIENTOS PARA SU OBTENCION. SEGUN LA INVENCION, LAS SALES FISIOLOGICAMENTE ACEPTABLES DE LOS COMPUESTOS PUEDEN SER SALES DE SUSTANCIAS, SEGUN LA INVENCION, CON ACIDOS MINERALES, ACIDOS CARBOXILICOS O ACIDOS SULFONICOS. COMO SALES, PUEDEN INDICARSE SALES DE BASES CONVENCIONALES, COMO POR EJEMPLO SALES DE METALES ALCALINOS O SALES DE AMONIO, DERIVADOS DE AMONIACO O AMINAS ORGANICAS.
GT200000011A 1999-02-04 2000-02-03 Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevos materiales. GT200000011A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19904389A DE19904389A1 (de) 1999-02-04 1999-02-04 Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe

Publications (1)

Publication Number Publication Date
GT200000011A true GT200000011A (es) 2001-07-27

Family

ID=7896332

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000011A GT200000011A (es) 1999-02-04 2000-02-03 Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevos materiales.

Country Status (5)

Country Link
AR (1) AR022469A1 (es)
AU (1) AU2110000A (es)
DE (1) DE19904389A1 (es)
GT (1) GT200000011A (es)
WO (1) WO2000045799A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6320998A (en) 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
HRP20050168A2 (en) 2002-08-23 2005-10-31 Rigel Pharmaceuticals Pyridyl substituted heterocycles useful for treating or preventing hcv infection
WO2004099164A1 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
JP2008515992A (ja) * 2004-10-13 2008-05-15 ピーティーシー セラピューティクス，インコーポレーテッド 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用
JP2008540425A (ja) 2005-05-02 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用
US20080306124A1 (en) * 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
CN101511827B (zh) 2006-09-07 2012-02-01 埃科特莱茵药品有限公司 作为免疫调制剂的吡啶-4-基衍生物
CA2661315C (en) * 2006-09-08 2015-11-24 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
SI2125797T1 (sl) 2007-03-16 2014-03-31 Actelion Pharmaceuticals Ltd. Derivati amino-piridina kot agonisti receptorja s1p1/edg1
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
ES2455197T3 (es) 2007-12-07 2014-04-14 Abbvie Deutschland Gmbh & Co Kg Derivados de oxindol 5,6-disustituidos y el uso de los mismos para la preparación de un medicamento para el tratamiento de enfermedades dependientes de vasopresina
BRPI0820668A2 (pt) 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CA2707667C (en) 2007-12-07 2016-02-23 Abbott Gmbh & Co. Kg Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
CA2766643C (en) 2009-07-08 2017-01-03 Dermira (Canada), Inc. Tofa analogs useful in treating dermatological disorders or conditions
EP2454255B1 (en) 2009-07-16 2013-11-06 Actelion Pharmaceuticals Ltd. Pyridin-4-yl derivatives as s1p1/edg1 agonists
ES2544086T3 (es) 2011-01-19 2015-08-27 Actelion Pharmaceuticals Ltd. Derivados de 2-metoxi-piridin-4-ilo
CN102329277B (zh) * 2011-10-24 2013-08-07 海南霞迪药业有限公司 一种制备帕瑞昔布的方法
PH12017502097B1 (en) 2015-05-20 2023-05-05 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
CN116535399B (zh) * 2022-01-25 2024-02-27 中国药科大学 3-羟基-5-(异噁唑-5-基)吡啶甲酰甘氨酸类化合物、制法、药物组合物和应用
EP4567034A1 (en) * 2022-08-01 2025-06-11 Korea Institute of Science and Technology Novel heterocyclyl-phenyl-methylamine derivative, preparation method therefor, and use thereof for prevention, alleviation, or treatment of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB149877A (en) * 1919-11-22 1920-08-26 Arthur William Wells Improvements in and in connection with safety razors
DE3065860D1 (en) * 1979-02-22 1984-01-19 Monsanto Co Thermolysis of 2-(3-aryl-isoxazol-5-yl)benzoic acids, salts and halides from 3'-(aryl)-spiro(isobenzofuran-1(3h),5'(4'h)isoxazol)-3-ones
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
DE4314966A1 (de) * 1993-05-06 1994-11-10 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte Isoxazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
WO1997019039A1 (en) * 1995-11-17 1997-05-29 Novartis Ag Solid phase synthesis of heterocyclic compounds and combinatorial compound library
DE19640370C1 (de) * 1996-09-30 1998-02-12 Dornier Gmbh Lindauer Webmaschine mit Vorrichtungen zum Aufnehmen und Führen von Schaftstangen
EP0994101A4 (en) * 1997-06-18 2002-05-02 Fujisawa Pharmaceutical Co NEW PREPARATION PROCESS

Also Published As

Publication number Publication date
AU2110000A (en) 2000-08-25
WO2000045799A2 (de) 2000-08-10
DE19904389A1 (de) 2000-08-10
WO2000045799A3 (de) 2002-01-24
AR022469A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
GT200000011A (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevos materiales.
UY28034A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion asi como su empleo como medicamentos
UY28040A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos.
GT199800158AA (es) Agonistas de prostaglandinas y su uso para tratar trastornos oseos
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
PA8524401A1 (es) DERIVADOS DE 4-Fenil-piridin
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
CR20120007A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
ES2134755T3 (es) Derivados de quinolina como antagonistas de leucotrieno d4, composiciones que contienen los mismos y procedimientos para su preparacion.
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
AR028948A1 (es) Compuestos novedosos
ID18883A (id) Pesaing 5-ht 1f
PA8583201A1 (es) Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)
PA8452701A1 (es) Agonistas de prostaglandinas
AR027113A1 (es) Piperidinas sustiutidas, medicamentos que contienen estos compuestos y procedimiento par su preparacion
ES2067874T3 (es) Derivados de acetamida.
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2084996T3 (es) Piperazinas sustituidas utiles como agentes para el sistema nervioso central.
ES2166046T3 (es) Derivados de arilacrilamida como agonistas o antagonistas de 5ht1.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
MX16046A (es) Procedimiento para la preparacion de 2-amino-1,2,3,4-tetrahidronaftalenos substituidos en el anillo,compuesto obtenido y composicion farmaceutica que lo incluye
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion